ALDX Stock Analysis: Buy, Sell, or Hold?
ALDX - Aldeyra Therapeutics, Inc.
$1.93
-0.14 (-6.76%)
▼
5d:
-15.35%
30d:
+14.2%
90d:
+8.43%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When ALDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
4 traders called ALDX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ALDX is down 15.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ALDX is down 15.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ALDX is currently trading at $1.93, which is considered fair relative to its 30-day fair value range of $1.73 to $2.17. From a valuation perspective, the stock is trading at a discount (Forward PE: -9.7) compared to its historical average (12.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ALDX is in a strong downtrend. Immediate support is located at $1.82, while resistance sits at $2.53. Short-term momentum is weak, with the stock down 6.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.17 (+271.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALDX is in a strong downtrend. Immediate support is located at $1.82, while resistance sits at $2.53. Short-term momentum is weak, with the stock down 6.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.17 (+271.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.73 -
$2.17
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.8%)
- BULLISH: Trading 271.3% below Wall St target ($7.17)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to -15.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.73 -
$2.17
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.82
Resistance Level
$2.53
Current Trend
Strong Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.65
Wall Street Target
$7.17
(+271.3%)
PE vs Historical
-9.7 vs 12.8
CHEAP
Share & Embed Analysis
Last updated: July 14, 2026 7:58 AM ET
Data refreshes hourly during market hours. Next update: 8:58 AM
Data refreshes hourly during market hours. Next update: 8:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALDX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Richard Douglas
BUY
70000 shares
2026-03-19
Michael Alfieri
BUY
5000 shares
2026-03-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 64 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$124 | 61 BUY |
